Po-Lin Huang

Title: Po-Lin Huang: Innovator in Cancer Therapeutics

Introduction

Po-Lin Huang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer therapeutics, holding a total of 5 patents. His work focuses on developing innovative antibodies and proteins that enhance T-cell activation and cancer regulation.

Latest Patents

Among his latest patents is the development of bispecific CD137-binding antibodies for T-cell activation. These antibodies include an antigen binding region that binds to CD137, along with a second antigen binding region that targets an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Additionally, he has patented PD-L1 and OX40 binding proteins for cancer regulation. These proteins are designed to release inhibition through PD-L1 and stimulate T cells through OX40, showcasing his commitment to advancing cancer treatment.

Career Highlights

Po-Lin Huang is currently associated with Ap Biosciences Inc., where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential to improve cancer therapies and enhance patient outcomes.

Collaborations

He collaborates with notable colleagues, including Jhong-Jhe You and Ching-Hsuan Hsu, contributing to a dynamic research environment that fosters innovation.

Conclusion

Po-Lin Huang's contributions to cancer therapeutics through his patents and collaborations highlight his role as a leading inventor in the field. His innovative approaches are paving the way for new treatments that could significantly impact cancer care.